A Single Arm Phase II Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Poziotinib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 05 Nov 2019 Planned initiation date changed from 1 Apr 2019 to 1 Nov 2019.
- 28 Feb 2019 According to a Spectrum Pharmaceuticals media release, the company expects to initiate this pan-tumor study in H2 2019.
- 20 Feb 2019 Planned initiation date changed from 1 Feb 2019 to 1 Apr 2019.